Citi downgraded Edwards Lifesciences to Neutral from Buy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on EW:
- Edwards Lifesciences price target raised to $77 from $75 at Baird
- Edwards Lifesciences price target lowered by $7 at Barclays, here’s why
- Edwards Lifesciences approves $1B of additional share repurchase authorization
- Edwards Lifesciences sees FY24 adjusted EPS $2.70-$2.80, consensus $2.80
- Edwards Lifesciences backs FY23 adjusted EPS view $2.47-$2.53, consensus $2.51